Cargando…

Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments

Cancer has been the leading cause of mortalities, with lung cancer contributing 18% to overall deaths. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The primary form of therapy used to treat lung cancer still includes oral and systemic administration of drugs, radiot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Chetna, Jaipuria, Aadya, Gupta, Nikesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861595/ https://www.ncbi.nlm.nih.gov/pubmed/36678768 http://dx.doi.org/10.3390/pharmaceutics15010139

Ejemplares similares

Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes
por: Parvathaneni, Vineela, et al.
Publicado: (2021)

Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC)
por: Chauhan, Gautam, et al.
Publicado: (2023)

Visible Laser Light Mediated Cancer Therapy via Photothermal Effect of Tannin-Stabilized Magnetic Iron Oxide Nanoparticles
por: Gupta, Nikesh, et al.
Publicado: (2023)

Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment
por: Parvathaneni, Vineela, et al.
Publicado: (2020)

Staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2006)

From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids
por: Nave, Ruediger, et al.
Publicado: (2013)

Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood–Brain Barrier (BBB)
por: Ghorai, Soma Mondal, et al.
Publicado: (2023)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Inhaled Cisplatin for NSCLC: Facts and Results
por: Kosmidis, Christoforos, et al.
Publicado: (2019)

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)
por: Zhang, Jiashuai, et al.
Publicado: (2023)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Targeting of Inhaled Therapeutics to the Small Airways: Nanoleucine Carrier Formulations
por: Miller, Danforth P., et al.
Publicado: (2021)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization
por: Eedara, Basanth Babu, et al.
Publicado: (2023)

Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2022)

Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications
por: Zheng, Zhanying, et al.
Publicado: (2021)

Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer
por: Gandhi, Sona, et al.
Publicado: (2023)

Advances in radiological staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2004)

Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival
por: Wang, Zhaoxi, et al.
Publicado: (2015)

ASCO 2020 non-small lung cancer (NSCLC) personal highlights
por: Horvath, Lena, et al.
Publicado: (2021)

An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)
por: Murphy, Ciara, et al.
Publicado: (2023)

Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
por: Su, Shu, et al.
Publicado: (2023)

Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices
por: Saha, Tushar, et al.
Publicado: (2022)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Formulation and Development of Metered Dose Inhalations of Salbutamol in Solution Form
por: Khale, Anubha, et al.
Publicado: (2011)

Inhalational System for Etoposide Liposomes: Formulation Development and In Vitro Deposition
por: Parmar, J. J., et al.
Publicado: (2011)

Development of Inhalable Spray Dried Nitrofurantoin Formulations for the Treatment of Emphysema
por: Leslie, Mathew N., et al.
Publicado: (2022)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

IGDB.NSCLC: integrated genomic database of non-small cell lung cancer
por: Kao, Sen, et al.
Publicado: (2012)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
por: Guo, Shicheng, et al.
Publicado: (2015)

CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
por: Wald, Ori
Publicado: (2018)

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis
por: Fang, Rui, et al.
Publicado: (2018)

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Chiu, Li-Chung, et al.
Publicado: (2021)

Uniportal VATS for Diagnosis and Staging in Non-Small Cell Lung Cancer (NSCLC)
por: Del Campo, Jone Miren, et al.
Publicado: (2023)

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
por: Lange, Ansgar, et al.
Publicado: (2014)

Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)
por: Gridelli, Cesare, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2188uhjg9rkricb98m96gkd7kl